Dong-Kyu Lee1, Euiyeon Na2, Seongoh Park3, Jeong Hill Park1,2, Johan Lim3, Sung Won Kwon1,2. 1. Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. 2. College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea. 3. Department of Statistics, Seoul National University, Seoul 08826, Republic of Korea.
Abstract
Cancer detection relying on the release of volatile biomarkers has been extensively studied, but the individual biochemical processes of the cells from which biogenic volatiles originate have not been thoroughly elucidated to date. Inadequate determination of the metabolic origin of the volatile biomarkers has limited the progress of the scientific and practical applications of volatile biomarkers. To overcome the current limitations, we developed a metabolism tracking approach combining stable isotope labeling and flux analysis of volatiles to trace the intracellular metabolism-derived volatiles and to reveal their relation to cancer metabolic pathways. Specifically, after the 13C labeling of lung cancer cell, the isotopic ratio of whole cellular carbon was measured by nanoscale secondary ion mass spectrometry-based imaging. The kinetic modeling with the time-dependent isotopic ratio determined the period during which cancer cells reach the metabolic steady state, at which time all of the potential volatiles derived from intracellular metabolism were fully enriched isotopically. By measuring the isotopic enrichment of volatiles at the end-stage of isotopic flux, we found that 2-pentadecanone appeared to be derived from the metabolic cascade starting from glucose to fatty acid synthesis. Furthermore, this biosynthetic pathway was determined to be distinct in cancer, as it was upregulated in colon, breast, and pancreatic cancer cells but not in normal cells. The investigation of the metabolic footprint of 2-pentadecanone demonstrates that our novel approach could be applied to trace the metabolic origin of biogenic volatile organic compounds. This analytical strategy represents a potential cutting-edge tool in elucidating the biochemical authenticity of cancer volatiles and further expanding our understanding of the metabolic network of airborne metabolites in vitro.
Cancer detection relying on the release of volatile biomarkers has been extensively studied, but the individual biochemical processes of the cells from which biogenic volatiles originate have not been thoroughly elucidated to date. Inadequate determination of the metabolic origin of the volatile biomarkers has limited the progress of the scientific and practical applications of volatile biomarkers. To overcome the current limitations, we developed a metabolism tracking approach combining stable isotope labeling and flux analysis of volatiles to trace the intracellular metabolism-derived volatiles and to reveal their relation to cancer metabolic pathways. Specifically, after the 13C labeling of lung cancer cell, the isotopic ratio of whole cellular carbon was measured by nanoscale secondary ion mass spectrometry-based imaging. The kinetic modeling with the time-dependent isotopic ratio determined the period during which cancer cells reach the metabolic steady state, at which time all of the potential volatiles derived from intracellular metabolism were fully enriched isotopically. By measuring the isotopic enrichment of volatiles at the end-stage of isotopic flux, we found that 2-pentadecanone appeared to be derived from the metabolic cascade starting from glucose to fatty acid synthesis. Furthermore, this biosynthetic pathway was determined to be distinct in cancer, as it was upregulated in colon, breast, and pancreatic cancer cells but not in normal cells. The investigation of the metabolic footprint of 2-pentadecanone demonstrates that our novel approach could be applied to trace the metabolic origin of biogenic volatile organic compounds. This analytical strategy represents a potential cutting-edge tool in elucidating the biochemical authenticity of cancer volatiles and further expanding our understanding of the metabolic network of airborne metabolites in vitro.
A wide variety of airborne-released
metabolites, also known as
biogenic volatile organic compounds (BVOCs), have attracted interest
from researchers as potential diagnostic biomarkers of cancer.[1−3] Since the first discovery of the potential of volatile-based diagnosis
in the middle of the 20th century,[4] the
application of this type of diagnostic tool for the detection of cancer
has received considerable attention.[4] Furthermore,
in recent years, the advances in quantitative and qualitative techniques
to analyze BVOCs have enabled researchers to assess the volatile biomarkers
specific to cancer.[5] Along with the potential
for the volatile-based diagnosis, a volatile compound analysis combining
a variety of extraction methods and detectors has been developed.[6−8] Thanks to these techniques, cancer researchers revealed the composition,
dynamics, or alterations of cancer volatiles emitted in the breath,
tissues, fluids, and tumor cells of cancerpatients.[9,10] For example, humanlung cancer and gastric cancer, which are of
particular interest because these organs could come into contact with
the exhaled breath, appeared to release distinctive cancer volatiles.[11−16] Furthermore, in vitro experiments using cancer
cells, the smallest unit of cancer, were also conducted, and a variety
of volatiles, including aldehydes and hydrocarbons, were identified
as cancer volatiles.[9,17] In summary of the previous discoveries,
a wide variety of BVOCs released specifically from various types of
cancer were identified as discriminative BVOCs for cancer.[18]However, previous studies utilized conventional
methods that could
not determine whether the volatiles known as cancer biomarkers are
biochemically emitted by and derived from the intracellular metabolism
of cancer cells. Most of the studies using cancer cells have been
limited to just comparing the amounts of BVOCs in normal and cancer
cells. The problem is that this approach cannot clearly establish
their cancer-specific biochemical origin. To date, there is no robust
evidence regarding the association between BVOCs and their biosynthetic
pathways, and only theoretical estimates of their biochemical origin,
based on the classes of each compound, have been studied.[1,3] To dispel the uncertainty regarding the origins of the cancer volatiles,
it is necessary to precisely examine the cancer-specific intracellular
metabolic pathways from which volatiles arise.In this study,
a method for tracking intracellular metabolism that
generates volatiles was developed as a breakthrough in solving the
aforementioned issues. We applied stable isotope-assisted metabolic
labeling to elucidate cancer metabolism-specific volatiles.[19,20] Specifically, we used [U–13C]glucose, which is
a major source of carbon via the Warburg effect of cancer cells, as
a labeling agent.[21] To determine when 13C from glucose was enriched completely in every volatile
candidate, we defined the moment when the cells reached the isotopic
steady state using nanoscale secondary ion mass spectrometry (nanoSIMS),
as it offers an outstanding spatial resolution adequate for cell samples.[22,23] At the steady state, cancer metabolism-derived volatiles were sorted
from uncertain volatiles by isotopic influx, which was detected by
headspace–solid phase microextraction (HS–SPME) and
gas chromatography–mass spectrometry (GC–MS).[24,25]
Results and Discussion
Mass Spectrometry-Based Cellular Imaging
Measures the Intracellular 13C Flux
A platform
for tracking intracellular metabolism-derived
volatiles is shown in Figure a,b. The main purpose of this platform is to trace all the
volatiles synthesized metabolically, starting from the first isotope-labeled
metabolite. Because we sought to observe unknown isotopic flux into
volatiles and their related pathways, it was necessary to verify that
the isotopic distribution into all of the possible volatiles was complete.[23,26] It is worth mentioning that the metabolic fluxes represent a relatively
narrow range of carbon metabolism, which makes metabolites insufficient
to account for whole cellular carbon located in a complex biochemical
network. The isotopic fluxes measured at the metabolite level rapidly
changed compared to the results of the intracellular carbon discussed
later in this section (Note S1 and Table S1). Accordingly, we determined the time for reaching an isotopic steady
state of whole cellular carbon using nanoSIMS. At first, we selected
CN as a detected ion because this ion could selectively detect cell-specific
carbon and had a lower background noise (Figure S1). By measuring 13C14N (27.05 m/z) and 12C14N (26.03 m/z), we observed time-dependent 13C/12C above the natural ratio after labeling 13C-glucose for 14 days (Figure a). These cellular images at various times indicated that
the rate of 13C enrichment in cellular components slowed
down slightly between 4 and 7 days.
Figure 1
(a) Platform for tracing intracellular
metabolism-derived volatile
compounds. (b) Schematic illustration of finding cancer volatiles
produced by cancer-specific metabolism. Red-highlighted features indicate
isotopically enriched compounds.
Figure 2
Cellular imaging by nanoSIMS for measuring carbon flux and steady
state in whole cellular components. (a) Cellular shapes (12C14N) and corresponding 13C/12C
ratios after isotope labeling. The rainbow scale indicates the 13C/12C ratio ranging from blue (0) to red (20).
The intensity of pixels designated as green bars was measured for
calculating the average 13C/12C ratio of each
cell. Scale bars, 10 μm. (b) Determination of isotopic pseudosteady
state (PSS) of the cellular carbon. The average 13C/12C ratio of each cell measured in Figure a (n = 3 for each time point)
is plotted as % above the natural ratio (black dots). The red curve
for 13C flux was obtained by fitting 18 data points to
the kinetic model. Time to 6.73 days, where the increment of 13C/12C ratio was reached, was selected as a PSS.
(c) Rate of increment of 13C at each time point. The first
derivative of the curve in Figure b is plotted.
(a) Platform for tracing intracellular
metabolism-derived volatile
compounds. (b) Schematic illustration of finding cancer volatiles
produced by cancer-specific metabolism. Red-highlighted features indicate
isotopically enriched compounds.Cellular imaging by nanoSIMS for measuring carbon flux and steady
state in whole cellular components. (a) Cellular shapes (12C14N) and corresponding 13C/12C
ratios after isotope labeling. The rainbow scale indicates the 13C/12C ratio ranging from blue (0) to red (20).
The intensity of pixels designated as green bars was measured for
calculating the average 13C/12C ratio of each
cell. Scale bars, 10 μm. (b) Determination of isotopic pseudosteady
state (PSS) of the cellular carbon. The average 13C/12C ratio of each cell measured in Figure a (n = 3 for each time point)
is plotted as % above the natural ratio (black dots). The red curve
for 13C flux was obtained by fitting 18 data points to
the kinetic model. Time to 6.73 days, where the increment of 13C/12C ratio was reached, was selected as a PSS.
(c) Rate of increment of 13C at each time point. The first
derivative of the curve in Figure b is plotted.
Kinetic Modeling for Estimation of Isotopic Pseudosteady State
Determines the End-Stage of 13C Enrichment
We
further quantified the average 13C/12C ratio
of the cells (Figure a and Figure S2), and an isotopic pseudosteady
state (PSS) of the cellular carbon was assumed over a nonlinear least-squares
method modeled by a modified Michaelis–Menten kinetics equation
as two substrate reactions (Figure b).[27] We utilize the nonlinear
least-squares method to examine a trend that properly explains the
fluctuation in the data. Specifically, we aim to investigate a point
of steady state in a carbon flux. Throughout the following discussion,
we assume the true model is increasing without loss of generality,
as seen in Figure b since the decline can be accounted for after being reflected by
a horizontal axis. Our model equation is written as y = (Vx2)/(K + x2) + c, where x and y denote time (in days or hours) and the increment
of carbon flux, respectively. V represents the total
variation of y which can be explained by the model,
and K is the constant that determines the time point
when reaching 0.5V + c. The last
two values are parameters of the model to be estimated from data points.
It is noted that c is a prespecified constant required
to set the baseline on y. For example, c is set to 100 in Figure since we convert all values to a relative scale (in percent)
based on the value at day 0. Also, c represents the
minimum value of the function while Vmax = V + c indicates the maximum value we can achieve.
To estimate the coefficients K and V, we implement the Gauss–Newton algorithm using the “nls”
function in R language. In this kinetic model, the model equation
with estimated parameters V̂ = 252.18 and K̂ = 15.06 is given by y = (252.18x2)/(15.06 + x2)
+ 100 where c is set to 100. For a measurement of
the goodness-of-fit of our model, the coefficient of determination R2 is used here, which is defined as where ŷ is the fitted value of ith data, and y̅ is the average of y’s.[28] As we obtain R2 = 0.80, it
can be said that approximately 80% of our data are accounted for by
the nonlinear function, which implies the high reliability of the
fitting. It is noted that our model equation implicitly postulates
that the rate of increment gradually decreases. Therefore, we define
the PSS as the point when an increment from the reference level becomes
0.75 of the whole variation V (Vst in Figure b). The red line in Figure b represents the fitted model based on 18 data points
(black dots), of which values were derived from the average intensity
of pixels along the green bars in Figure a, and Vmax = V̂ + c = 352.18 and Vst = 0.75V̂ + c = 289.14. In Figure c, the first derivative (instantaneous rate of change) of the function
is drawn, which shows how rapidly y grows; when it
is larger, y increases more rapidly. It reveals that
the maximum rate of increment is approximately 42.20 (%/day) at 2.8
days; thereafter, the rate begins to decline, reaching one-third (14.05)
of the maximum at the steady state. It implies that y tends to increase as much as 42.20% in 1 day at 2.8 days, but only
14.05% per day at 6.73 days. Observation of a gradual change in y after 6.73 days (Figure b) underlies that this time point nears the steady
state. This result reflects the PSS, the minimal time for analyzing
volatiles by ensuring the near completion of the isotopic enrichment.
The PSS at 6.73 days indicated that every volatile potentially produced
from glucose metabolism could be labeled completely if A549 cells
were cultured for 7 days.
Isotopic Flux Analyses Trace the Intracellular
Metabolism-Derived
Volatiles
In PSS, we identified intracellular metabolism-derived
airborne metabolites. Because there was no evidence that potential
volatiles arose from intracellular metabolism, nontargeted volatile
profiling in vitro using HS–SPME coupled with
GC–MS was performed using optimal extraction parameters (Figure S3 and Note S2).[29] The optimized method using divinylbenzene/carboxen/polydimethylsiloxane
(DVB/CAR/PDMS) fiber with a 24 h extraction time detected 99 volatile
and semivolatile compound features released from A549 lung cancer
cells, out of which 40 compounds were identified (Table S2). As we observed the 13C enrichment, noticeably,
only 2-pentadecanone showed an increased heavy isotope ratio in the
mass spectrum (Figure a). This finding indicated that 2-pentadecanone may be the only molecule
derived from the cellular metabolism of glucose. Other volatiles were
not significantly enriched by 13C-glucose labeling (Figure S4). The mass distribution vector (MDV)
of 2-pentadecanone during isotope labeling revealed that cancer cells
produce this compound from at least two types of substrates (Figure b and Table S3). m+0, the monoisotopic mass of molecules,
dramatically decreased at 1 day, estimated to reach the PSS at 0.21
days, and was maintained at that ratio until 7 days. However, m+3,
which includes three isotopes in the molecule, did not follow the
adjusted kinetic model. After a period of rapid increase at 1 day
(up to 37.2%), m+3 exhibited a decreasing trend. The decreased proportion of m+3 was possibly due to the induction
of the isotopologues over m+3 (≥m+4) from 2 days. These data
indicated the rapid uptake of three 13C from one substrate
and the slower uptake of other carbons from the other substrates,
which in turn demonstrated that 2-pentadecanone was synthesized from
two types of isotope-labeled metabolites. Moreover, the positional
influx of 13C was verified by inspecting the isotopologues
of multiple fragment ions from 2-pentadecanone (Figure a and Table S3).[30] Many fragments consisting of only
carbons and hydrogens (six CH2) appeared to show a slight decrease of m+0 at
1 day, but C3H6O containing a carbonyl group
with three carbons underwent a sharp decrease by 43.3% (Figure c). Accordingly, the three-carbon
uptake as explained above occurred on the side of the carbonyl group
among the 15 carbons of 2-pentadecanone. The different influx ratios
of these three carbons and others may suggest that 2-pentadecanone
is derived from two different intracellular metabolites. However,
the nature of the specific substrates is unknown.
Figure 3
The 2-pentadecanone is identified as the only volatile derived
from glucose metabolic cascade in cancer cells. (a) 13C-labeled
(blue) and unlabeled (red) spectrum of 2-pentadecanone and its fragment
ions. (b) Mass distribution vector (MDV, %) of 2-pentadecanone (precursor
ion, 226 m/z). m+0 indicates the
relative abundance of monoisotopic mass, and m+1 to m+4 stand for
the abundance of molecules with one to four isotopes. (c) MDV (%)
of seven fragment ions corresponding to each molecular part. In parts
b and c, x-axis indicates the time after start of 13C labeling. Data are presented as mean and SEM.
The 2-pentadecanone is identified as the only volatile derived
from glucose metabolic cascade in cancer cells. (a) 13C-labeled
(blue) and unlabeled (red) spectrum of 2-pentadecanone and its fragment
ions. (b) Mass distribution vector (MDV, %) of 2-pentadecanone (precursor
ion, 226 m/z). m+0 indicates the
relative abundance of monoisotopic mass, and m+1 to m+4 stand for
the abundance of molecules with one to four isotopes. (c) MDV (%)
of seven fragment ions corresponding to each molecular part. In parts
b and c, x-axis indicates the time after start of 13C labeling. Data are presented as mean and SEM.
2-Pentadecanone is a Cancer-Specific Volatile
Modulated by Fatty
Acid Synthesis
We found 2-pentadecanone to be produced during
fatty acid synthesis, the most common characteristic of the abnormal
proliferation of cancer cells.[31] In fact,
it can be easily assumed that 2-pentadecanone with a long hydrocarbon
chain is structurally similar to fatty acids. Nevertheless, it has
not been investigated whether 13C from glucose is integrated
into this volatile via fatty acid synthesis. Therefore, we first observed
the metabolic flux in central carbon metabolism including glucose
and fatty acids. Specifically, metabolites that have a higher isotopic
enrichment than 2-pentadecanone were specified, assuming the upstream
metabolic source should have a higher enrichment than a product (Figure a and Table S1). Most metabolites in the pathway, from
glucose to palmitic acid (C16:0 fatty acid), exhibited higher levels
of 13C enrichment than 2-pentadecanone. These data indicated
that upstream substrates may be involved in the synthesis of 2-pentadecanone.
Regarding palmitic acid, we inhibited fatty acid synthesis by treating
A549 cells with two feedback inhibitors, palmitic and oleic acid,
to determine if the synthesis of 2-pentadecanone was altered (Figure b).[32] As a result, the abundance of 2-pentadecanone was decreased
by both inhibitors compared with the control.
Figure 4
The 2-pentadecanone is
related to fatty acid synthesis. (a) Measurement
of isotopic flux of metabolites in central carbon metabolism. A decrease
of monoisotopic peak (m+0, green line) reflects a time-dependent 13C flux of metabolites. Each box is colored on the basis of
the percentage of 13C enrichment (Vmax from the adjusted kinetic model). Data are presented as
mean and SEM. (b) Release of 2-pentadecanone after treatment with
the fatty acid synthesis inhibitors, palmitic acid (PA) and oleic
acid (OA). Data are shown as mean and SEM. *p <
0.05, **p < 0.01 by Student’s t test. Abbreviations are included in Note S1.
The 2-pentadecanone is
related to fatty acid synthesis. (a) Measurement
of isotopic flux of metabolites in central carbon metabolism. A decrease
of monoisotopic peak (m+0, green line) reflects a time-dependent 13C flux of metabolites. Each box is colored on the basis of
the percentage of 13C enrichment (Vmax from the adjusted kinetic model). Data are presented as
mean and SEM. (b) Release of 2-pentadecanone after treatment with
the fatty acid synthesis inhibitors, palmitic acid (PA) and oleic
acid (OA). Data are shown as mean and SEM. *p <
0.05, **p < 0.01 by Student’s t test. Abbreviations are included in Note S1.In addition, the release of 2-pentadecanone
was highly dependent
upon cancer cells. Among the investigated volatiles, only the release
of 2-pentadecanone showed a clear linear correlation with the cell
population, with a large coefficient (r; 0.994) and
a significant p-value for the null hypothesis test
of regression slope (p < 0.0001) (Figure S5, Table S2, and Note S3). In addition,
the incorporation of 13C into this compound was highly
enriched in other types of cancer cells including breast cancer (MDA-MB-231),
colon cancer (DLD-1), and pancreatic cancer (MIA-PaCa-2) cells, but
not in normal lung (IMR-90, HEL 299 and LL 24), normal colon (CCD-18Co),
and normal liver (HL-7702) cells (Figure ). After labeling for 7 days, the cancer
groups had increased ratios of labeled to unlabeled form. On the contrary,
the normal cells had an approximately equal labeled/unlabeled ratio
as compared to that of the control (without 13C-glucose),
and this observation held true in HEL 299, LL 24, HL-7702, and CCD-18Co
cells, wherein the unpaired t test between cell lines
with 13C (four cancer cells and five normal cells) and 12C-glucose (A549) clearly showed the significant alteration
of the ratio in cancer cells only (Figure S6). These results support the notion that 2-pentadecanone is strongly
associated with fatty acid synthesis beginning from glucose in cancer
cells.
Figure 5
Isotope abundance of 2-pentadecanone released by normal cells (lung,
IMR-90, HEL 299, and LL 24; colon, CCD-18Co; liver, HL-7702) and cancer
cells [control (12C-Glc) and 13C-glucose-treated
(13C-Glc) A549, lung cancer; DLD-1, colon cancer; MDA-MB-231,
breast cancer; and MIA PaCa-2, pancreatic cancer]. m+0 and m+1 indicate
the unlabeled (black) and labeled (red) forms, respectively. Average
labeled/unlabeled ratio with SEM is shown on top right.
Isotope abundance of 2-pentadecanone released by normal cells (lung,
IMR-90, HEL 299, and LL 24; colon, CCD-18Co; liver, HL-7702) and cancer
cells [control (12C-Glc) and 13C-glucose-treated
(13C-Glc) A549, lung cancer; DLD-1, colon cancer; MDA-MB-231,
breast cancer; and MIA PaCa-2, pancreatic cancer]. m+0 and m+1 indicate
the unlabeled (black) and labeled (red) forms, respectively. Average
labeled/unlabeled ratio with SEM is shown on top right.
Conclusion
In this paper, we applied
a novel analytical platform to trace
intracellular metabolism-derived volatiles and established the relationship
between volatiles and cancer-specific metabolism. At the cellular
steady state determined by nanoSIMS-based imaging and kinetic modeling,
we successfully elucidated the isotopic enrichment into 2-pentadecanone,
the only volatile that originated from the metabolic cascade beginning
with 13C-glucose. This phenomenon was found to be regulated
by fatty acid synthesis and to be a universal feature of various types
of cancer cells. The novel insight into this previously unexamined
compound in cancer research can expand our understanding of new regulatory
mechanisms regarding the emissions of volatile compounds at the cellular
level. Future studies are warranted to provide better insights into
the biochemical origin of a wide range of volatile compounds using
this approach as a solution to address the bottleneck in biogenic
volatile compound studies.
Materials and Methods
Chemicals and Reagents
[U–13C]glucose
was purchased from Cambridge Isotope Laboratories (Tewksbury, MA).
ATCC-modified RPMI1640 medium with phenol red, Dulbecco’s phosphate-buffered
saline, fetal bovine serum, trypsin-EDTA solution, and antibiotic-antimycotic
solutions were from Life Technologies (Gaithersburg, MD). Acetone,
methanol, 2-propanol, and water (HPLC grade) were from J.T. Baker
(Center Valley, PA). Reagents for cell fixation, epoxy embedding,
derivatization of metabolites, and all standards for metabolite identification
were from Sigma-Aldrich (St. Louis, MO).
Cell Culture Conditions
and Stable Isotope Labeling
A549, DLD-1, MIA-PaCa-2, MDA-MB-231,
IMR-90, HEL 299, and LL 24 cell
lines were purchased from the Korean Cell Line Bank (Seoul, Korea).
All cell lines were maintained in ATCC-modified RPMI1640 medium supplemented
with 10% fetal bovine serum and 1% antibiotic-antimycotic solution.
The cells were maintained in T-75 culture flasks (Life Technologies)
at 37 °C and 5% CO2. Isotope labeling was performed
with the same concentration (4.5 g/L) of [U–13C]glucose
in glucose-free RPMI1640. Before immersing the cell lines in the labeled
medium, we cultured all cell lines simultaneously in unlabeled medium
until they reached a metabolic steady state. After labeling began,
we changed the media daily to sustain an adequate concentration of 13C to fully enrich volatile compounds. At 24 h before volatile
compound analysis, we transferred 1 × 106 cells into
glass bottles.
Nanoscale Secondary Ion Mass Spectrometry-Based
Cellular Imaging
The preparation of cell samples for nanoSIMS
began by fixation
in a 2.5% glutaraldehyde and 4% paraformaldehyde mixture in 0.1 M
phosphate buffer for 3 h at room temperature. Then, 1% osmium tetroxide
was added as a secondary fixative, and cells were incubated for 2
h at 4 °C. They were washed three times with distilled water
and dehydrated with increasing concentrations of acetone (30%, 60%,
90%, and 100% with 2 repeats). After dehydration, gradually increasing
concentrations of epoxy embedding solution on acetone were added to
the dehydrated cells (50%, 75%, and 100% embedding ingredient in acetone).
Epoxy resins were polymerized at 45 °C for 12 h, followed by
24 h at 60 °C. Embedded samples were sliced using an ultramicrotome
(EM UC7; Leica, Wetzlar, Germany) and were deposited onto silicon
wafers (6 × 6 mm, 0.5 mm thick; Sigma-Aldrich). MS-based cell
imaging was performed using a NanoSIMS 50 (Cameca, Courbevoie, France)
at the Korea Basic Science Institute (KBSI). The primary Cs+ ion set to 16 keV collision energy was used for presputtering at
160 pA for 30 min and sputtering at 0.9 pA for 33 min. An ion beam
was focused onto a 50 nm nominal spot on the sample surface during
the analysis. The beam was rastered over a square region of 40 ×
40 μm with a scanning resolution of 256 × 256 pixels. To
measure carbon isotope abundances, we choose 13C14N and 12C14N as detected ions for calculating
the 13C/12C ratio (Figure S1). The mass resolving power (MRP) with a coaxial path of
primary and secondary ion beam was greater than 5000 to differentiate
the 13C14N ion from 12C15N, which is 0.007 m/z heavier.
Analysis of Volatile Organic Compounds (VOCs)
VOC extraction in vitro employed a headspace–SPME technique as previously
described.[29] Polyacrylate (PA) 85 μm,
polydimethylsiloxane (PDMS) 100 μm, carboxen/polydimethylsiloxane
(CAR/PDMS) 75 μm, polydimethylsiloxane/divinylbenzene (PDMS/DVB)
65 μm, and divinylbenzene/carboxen/polydimethylsiloxane (DVB/CAR/PDMS)
50/30 μm fibers (Supelco, Bellefonte, PA) were conditioned at
temperatures and times recommended by the manufacturer. After the
cells were transferred into a glass bottle 24 h before the end of
each 13C labeling period (0–7 days), VOC extraction
using conditioned fibers was performed for 24 h. VOC-adsorbed fibers
were analyzed by GC–MS (GCMS-QP2010, Shimadzu, Tokyo, Japan)
equipped with a DB-5 ms capillary column (30 m × 0.25 mm, 0.25
μm; Agilent Technologies, Palo Alto, CA). VOCs adsorbed on fibers
were injected at the same temperature for conditioning in splitless
mode (sampling time 30 s). High-purity helium (1 mL/min constant flow)
was used as a carrier gas with the following column temperature program:
an initial temperature at 70 °C, an increase to 150 °C at
4 °C/min, a hold at 150 °C for 1 min, an increase to 280
°C at 5 °C/min, and a hold for 3 min, for a total of 50
min. The compounds were then ionized using electron impact (EI) mode
with a 70 eV filament at a 200 °C ion source temperature. The
mass detection range was 40–500 m/z, with a scan rate of 2500 s–1. A retention
index (RI) was calculated using alkane mixture (C7–C40). VOC
identification used RI (±50) and mass spectrum (similarity index
over 80) for comparison to the NIST library (NIST08, Gaithersburg,
MD); 2-pentadecanone was confirmed using standard data from a reference
compound.
Metabolites Extraction
Intracellular metabolites, including
fatty acid and polar metabolites, were extracted using a biphasic
extraction with direct solvent scraping method as previously described.[33] Cells for metabolite extraction were prepared
without any media change. After removing media with ice-cold water
three times, quenching and extraction were simultaneously achieved
by adding 2 mL of 80% methanol at −70 °C with internal
standards [5 μg/mL nonadecanoic acid (C19:0 fatty acid) for
fatty acids; 5 μg/mL glycine-d5,
succinic acid-d4, and citric acid-d4 for polar metabolites]. The collected cell
pellets were fully disrupted by three freeze/thaw cycles in liquid
N2 followed by ice-cold freezer. After the final cycle,
1 mL of chloroform was added to perform a liquid–liquid extraction
(LLE). Samples were vortexed for 10 s and centrifuged at 13 000g for 5 min, and the aqueous and organic phases were transferred
to Eppendorf tubes and glass vials, respectively. LLE was repeated
two more times. Collected organic phases were evaporated using a SpeedVac
instrument (Savant AES2010, Thermo Fisher Scientific, Waltham, MA),
and the aqueous phases were evaporated with a nitrogen purge.
Polar
Metabolite Profiling
Polar metabolites were derivatized
using a method previously described.[34] A
methoxyamine hydrochloride solution (100 μL of 20 mg/mL in pyridine)
was added to the polar metabolite extracts, and the reaction proceeded
for 90 min at 37 °C. The residues were trimethylsilylated using
the same volume of N,O-bis(trimethylsilyl)trifluoroacetamide
(BSTFA) solution with 1% trimethylchlorosilane (TMCS). Derivatized
samples were transferred to crimp vials and analyzed using the same
GC–MS used for VOC analysis, with some parameter modification.
The injection temperature was 300 °C, and the instrument was
operated in split mode (1:2). The column temperature program was slightly
changed as follows: an initial temperature of 80 °C for 2 min,
an increase to 100 °C at 4 °C/min, a hold for 3 min, an
increase to 200 °C at the same rate, a hold for 1 min, an increase
to 300 °C at 8 °C/min, and a hold for 2 min, for a total
of 50.5 min. All metabolites were identified using the same method
in VOC analysis, and the sugars and sugar phosphates were identified
using standard compounds.
Fatty Acid Profiling
Fatty acids
were derivatized using
acidic methanolysis as previously described.[35] A 1 mL portion of methanol/37% hydrochloric acid solution (4:1)
was added in a glass vial. Methylation was performed at 100 °C
for 120 min. After cooling to room temperature, 1 mL of hexane was
added for liquid–liquid extraction of methylated fatty acids
and repeated twice. Hexane layers were transferred to the glass vial
and reconstituted into 200 μL of hexane. GC–MS detection
and the fatty acid identification protocol were the same as for the
polar metabolites, and the column temperature program was modified
as follows: an initial temperature of 70 °C for 1 min, an increase
to 150 °C at 20 °C/min, an increase to 180 °C at 6
°C/min, an increase to 220 °C at 20 °C/min, a hold
for 1 min, an increase to 240 °C at 4 °C/min, and a hold
for 17 min, for a total of 35 min.
Data Processing and Statistical
Analysis
All GC–MS
data were aligned using MetAlign 3.0 software.[36] The extracted areas of isotopic m/z (mass to charge ratio) of each compound were chosen to
measure the abundance of labeled isotope. MDV, a corrected natural
abundance of each isotope (13C, 1.07%; 15N,
0.368%; 2H, 0.0115%; 17O, 0.038%; 18O, 0.205%; 29Si, 4.6832%; 30SI, 3.0872%), was
calculated using IsoCor, an MDV correction tool.[37] The corrected MDV of intracellular metabolites was mapped
onto the central carbon metabolism pathway using VANTED[38] connected to SBGN plugin.[39] NanoSIMS data were analyzed using WinImage software (Cameca)
to obtain 13C14N/12C14N and 12C14N images and ImageJ[40] with openMIMS plugin[41] software
(MIMS, Harvard University, Cambridge, MA; https://nano.bwh.harvard.edu/openMIMS) to extract the values of each detected ion. Linear regression analysis
and Pearson’s correlation coefficient for VOCs, and Michaelis–Menten
equation for calculating isotopic steady state were performed using
Graphpad Prism 7.0 software (Graphpad Software, Inc., San Diego, CA).
To estimate the coefficients K and V for every flux, we used the Gauss–Newton algorithm using
the “nls” function in R language.
Authors: Sacheen Kumar; Juzheng Huang; Nima Abbassi-Ghadi; Patrik Španěl; David Smith; George B Hanna Journal: Anal Chem Date: 2013-05-29 Impact factor: 6.986
Authors: Sean D Gates; Richard C Condit; Nissin Moussatche; Benjamin J Stewart; Alexander J Malkin; Peter K Weber Journal: Anal Chem Date: 2018-01-19 Impact factor: 6.986
Authors: Anton Amann; Ben de Lacy Costello; Wolfram Miekisch; Jochen Schubert; Bogusław Buszewski; Joachim Pleil; Norman Ratcliffe; Terence Risby Journal: J Breath Res Date: 2014-06-19 Impact factor: 3.262
Authors: Ana Rita Lima; Joana Pinto; Ana Isabel Azevedo; Daniela Barros-Silva; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Paula Guedes de Pinho; Márcia Carvalho Journal: Br J Cancer Date: 2019-10-07 Impact factor: 7.640
Authors: Ana Rita Lima; Joana Pinto; Filipa Amaro; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho Journal: Metabolites Date: 2021-03-19